Mathias Svahn

Chief Executive Officer • NextCell Pharma

Mathias Svahn is CEO and co-founder of NextCell Pharma AB,  a phase II cell therapy company. The lead drug candidate is ProTrans, an allogeneic mesenchymal stromal cell product with cells selected by the patent pending selection algorithm. In addition to diabetes, ProTrans is evaluated in two clinical trials for Covid-19, in Sweden and Canada.

He is member of the board of FamicordTX, a CAR-T start-up in oncology, member of ISCT Business Models and Investment Subcommittee and CEO of Cellaviva, Scandinavia’s largest stem cell bank for family saving stem cells.

Also Speaking

Lynn Fischer

Chief Executive Officer • TITLE21 Health Solutions

Ohad Karnieli

Founder & CEO • Adva Biotechnology

Jennifer Rabin

Next Gen Therapy Practice • Deloitte

Event Info


Fun Run